{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:59:40Z","timestamp":1795053580953,"version":"4.10.2"},"reference-count":20,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies that mostly have poor prognoses with currently available treatments. Upfront consolidation with autologous stem cell transplantation (ASCT) is frequently carried out, but its efficacy has never been investigated in randomized trials. We designed a multicenter, international, retrospective study with the main objective of comparing progression-free survival and overall survival of patients with PTCL who underwent ASCT in complete remission (CR) after first-line chemotherapy with a control group who did not undergo ASCT. From the initial population of 286 registered patients, 174 patients with PTCL other than anaplastic large cell lymphoma, ALK-positive, deemed fit for ASCT at the time of diagnosis, and who were in CR or uncertain CR after induction therapy (CR1) were included in our analysis. one hundred and three patients underwent ASCT, whereas 71 did not, in most cases (n=53) because the physician decided against it. With a median follow-up of 65.5 months, progression-free survival was significantly better in the transplanted patients than in the non-transplanted group: 63% versus 48% at 5 years (P=0.042). Overall survival was significantly longer for ASCT patients in the subgroup with advanced stage at diagnosis (5-year overall survival: 70% vs. 50%, P=0.028). In the multivariate analysis, first-line ASCT was associated with significantly prolonged progression-free survival (HR=0.57, 95% CI: 0.35-0.93) and overall survival (HR=0.57, 95% CI: 0.33-0.99). In conclusion, our study supports the use of ASCT as a consolidation strategy for patients with PTCL in CR1. These results should be confirmed in a prospective randomized study.<\/jats:p>","DOI":"10.3324\/haematol.2021.279426","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T15:06:17Z","timestamp":1648220777000},"page":"2675-2684","source":"Crossref","is-referenced-by-count":34,"title":["Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study"],"prefix":"10.3324","volume":"107","author":[{"given":"Alejandro Mart\u00edn","family":"Garc\u00eda-Sancho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bellei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"L\u00f3pez-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gritti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Dlouhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Moraleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Orsucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Garc\u00eda-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dodero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"De las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"L\u00f3pez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Gonz\u00e1lez","family":"De Villambrosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Bobillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"41374","doi-asserted-by":"crossref","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014; 124(10):1570-1577.","DOI":"10.1182\/blood-2014-04-573089"},{"key":"41375","doi-asserted-by":"crossref","unstructured":"d\u2019Amore F, Gaulard P, Trumper L. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5):v108-115.","DOI":"10.1093\/annonc\/mdv201"},{"key":"41376","doi-asserted-by":"crossref","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011; 2011:623924.","DOI":"10.5402\/2011\/623924"},{"key":"41377","doi-asserted-by":"crossref","unstructured":"Corradini P, Tarella C, Zallio F. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006; 20(9):1533-1538.","DOI":"10.1038\/sj.leu.2404306"},{"key":"41378","doi-asserted-by":"crossref","unstructured":"Rodriguez J, Conde E, Gutierrez A. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group. Eur J Haematol. 2007; 79(1):32-38.","DOI":"10.1111\/j.1600-0609.2007.00856.x"},{"key":"41379","doi-asserted-by":"crossref","unstructured":"Mercadal S, Briones J, Xicoy B. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008; 19(5):958-963.","DOI":"10.1093\/annonc\/mdn022"},{"key":"41380","doi-asserted-by":"crossref","unstructured":"Reimer P, Rudiger T, Geissinger E. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009; 27(1):106-113.","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"41381","doi-asserted-by":"crossref","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012; 30(25):3093-3099.","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"41382","doi-asserted-by":"crossref","unstructured":"Fossard G, Broussais F, Coelho I. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018; 29(3):715-723.","DOI":"10.1093\/annonc\/mdx787"},{"key":"41383","unstructured":"Swerdlow SH, Harris NL, Jaffe ES. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC. 2008."},{"key":"41384","doi-asserted-by":"crossref","unstructured":"Yam C, Landsburg DJ, Nead KT. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016; 91(7):672-676.","DOI":"10.1002\/ajh.24372"},{"key":"41385","doi-asserted-by":"crossref","unstructured":"Cederleuf H, Hjort Jakobsen L, Ellin F. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. Leuk Lymphoma. 2017; 58(12):2815-2823.","DOI":"10.1080\/10428194.2017.1300888"},{"key":"41386","doi-asserted-by":"crossref","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014; 25(11):2211-2217.","DOI":"10.1093\/annonc\/mdu443"},{"key":"41387","doi-asserted-by":"crossref","unstructured":"Park SI, Horwitz SM, Foss FM. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019; 125(9):1507-1517.","DOI":"10.1002\/cncr.31861"},{"key":"41388","doi-asserted-by":"crossref","unstructured":"Ahn S-Y, Jung S-Y, Jung S-H. Prognostic significance of FDG-PET\/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas. Ann Hematol. 2020; 99(1):83-91.","DOI":"10.1007\/s00277-019-03867-9"},{"key":"41389","doi-asserted-by":"crossref","unstructured":"Shah NN, Ahn KW, Litovich C. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?. Blood. 2021; 137(10):1416-1423.","DOI":"10.1182\/blood.2020007939"},{"key":"41390","doi-asserted-by":"crossref","unstructured":"Shadman M, Pasquini MC, Ahn KW. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022; 139(9):1330-1339.","DOI":"10.1182\/blood.2021013289"},{"key":"41391","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999; 17(4):1244.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"41392","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32(27):3048-3058.","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"41393","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279426\/74261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279426\/74980","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10581\/74261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:22Z","timestamp":1794045682000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279426","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}